Cargando…

Perspectives on statistical strategies for the regulatory biomarker qualification process

Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumula...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrix, Suzanne B, Mogg, Robin, Wang, Sue Jane, Chakravarty, Aloka, Romero, Klaus, Dickson, Samuel P, Sauer, John-Michael, McShane, Lisa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293027/
https://www.ncbi.nlm.nih.gov/pubmed/34037457
http://dx.doi.org/10.2217/bmm-2020-0523
_version_ 1783724940206276608
author Hendrix, Suzanne B
Mogg, Robin
Wang, Sue Jane
Chakravarty, Aloka
Romero, Klaus
Dickson, Samuel P
Sauer, John-Michael
McShane, Lisa M
author_facet Hendrix, Suzanne B
Mogg, Robin
Wang, Sue Jane
Chakravarty, Aloka
Romero, Klaus
Dickson, Samuel P
Sauer, John-Michael
McShane, Lisa M
author_sort Hendrix, Suzanne B
collection PubMed
description Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumulating, interpreting and analyzing available data is outlined, step-by-step, illustrated by a qualified enrichment biomarker example and a safety biomarker in the process of qualification. The detailed steps aid requestors seeking qualification of biomarkers, allowing them to organize the available evidence and identify potential gaps. This provides a statistical perspective for assessing evidence that parallels clinical considerations and is intended to guide the overall evaluation of evidentiary criteria to support a specific biomarker COU.
format Online
Article
Text
id pubmed-8293027
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-82930272021-07-22 Perspectives on statistical strategies for the regulatory biomarker qualification process Hendrix, Suzanne B Mogg, Robin Wang, Sue Jane Chakravarty, Aloka Romero, Klaus Dickson, Samuel P Sauer, John-Michael McShane, Lisa M Biomark Med Perspective Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumulating, interpreting and analyzing available data is outlined, step-by-step, illustrated by a qualified enrichment biomarker example and a safety biomarker in the process of qualification. The detailed steps aid requestors seeking qualification of biomarkers, allowing them to organize the available evidence and identify potential gaps. This provides a statistical perspective for assessing evidence that parallels clinical considerations and is intended to guide the overall evaluation of evidentiary criteria to support a specific biomarker COU. Future Medicine Ltd 2021-05-26 2021-06 /pmc/articles/PMC8293027/ /pubmed/34037457 http://dx.doi.org/10.2217/bmm-2020-0523 Text en © 2021 Pentara Corporation https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Perspective
Hendrix, Suzanne B
Mogg, Robin
Wang, Sue Jane
Chakravarty, Aloka
Romero, Klaus
Dickson, Samuel P
Sauer, John-Michael
McShane, Lisa M
Perspectives on statistical strategies for the regulatory biomarker qualification process
title Perspectives on statistical strategies for the regulatory biomarker qualification process
title_full Perspectives on statistical strategies for the regulatory biomarker qualification process
title_fullStr Perspectives on statistical strategies for the regulatory biomarker qualification process
title_full_unstemmed Perspectives on statistical strategies for the regulatory biomarker qualification process
title_short Perspectives on statistical strategies for the regulatory biomarker qualification process
title_sort perspectives on statistical strategies for the regulatory biomarker qualification process
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293027/
https://www.ncbi.nlm.nih.gov/pubmed/34037457
http://dx.doi.org/10.2217/bmm-2020-0523
work_keys_str_mv AT hendrixsuzanneb perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess
AT moggrobin perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess
AT wangsuejane perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess
AT chakravartyaloka perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess
AT romeroklaus perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess
AT dicksonsamuelp perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess
AT sauerjohnmichael perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess
AT mcshanelisam perspectivesonstatisticalstrategiesfortheregulatorybiomarkerqualificationprocess